Market capitalization | $30.75m |
Enterprise Value | $30.41m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.03 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-21.22m |
Free Cash Flow (TTM) Free Cash Flow | $-7.24m |
Cash position | $1.47m |
As a Free StocksGuide user, you can view scores for all 6,824 stocks worldwide.
1 Analyst has issued a forecast Coeptis Therapeutics:
1 Analyst has issued a forecast Coeptis Therapeutics:
Dec '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -20 -20 |
-
|
EBIT (Operating Income) EBIT | -21 -21 |
67%
67%
|
Net Profit | -21 -21 |
69%
69%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
Head office | United States |
CEO | David Mehalick |
Employees | 6 |
Founded | 2017 |
Website | coeptistx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.